The value of affinity determination in assay development and throughout drug development
The drive to lower drug dosage, improve healthcare and reduce costs has lead to the search for therapeutic antibodies with high target affinity. As a consequence, optimizing and monitoring the specificity and affinity of drug candidates to the target molecule has become critical in the development of therapeutic antibodies – from early screening of hybridomas or recombinant antibodies from phage display libraries, to affinity maturation and antibody engineering to improve the efficacy, safety and manufacturability of the final antibody drug product. Characterizing affinity is also important when selecting reagents for quantitative assays or assessing drug product activity in manufacturing release tests. The question is, how can high affinity be measured in the best possible way?
During our latest webinar, Johan Engström, Senior Scientist at Gyros Protein Technolgies gave a short introduction to Gyrolab technology and how you to set up and evaluate classical in-solution equilibrium experiments for determination of sub-nanomolar KD’s and active concentrations of interactants. Johan also gave examples of determinations of picomolar affinities for several marketed TNFα antagonists.
